Navigation Links
Genomic Health Announces Results From the Largest Genomic Analysis of Localized Clear Cell Renal Carcinoma at American Society of Clinical Oncology (ASCO) Annual Meeting
Date:6/4/2010

laboration with Pfizer Oncology for assessing prognosis in patients with stage 1-3 renal carcinoma, clear cell type, that has not spread to other parts of the body.

Researchers evaluated more than 700 candidate genes from 942 stage 1-3 clear cell renal carcinoma patients treated at Cleveland Clinic between 1985 and 2003.  Genomic factors strongly associated with risk of recurrence and clinical/pathologic covariates were identified.  The magnitude of hazard ratios was comparable to those of other clinically used prognostic markers, such as estrogen-receptor status and HER2 status in breast cancer.  Researchers suggest that these results could be used to create a multi-gene algorithm to predict recurrence of early-stage renal cell carcinoma.

"Genomic Health's collaboration with Pfizer represents an industry-leading example of academic, diagnostic and therapeutic organizations combining resources and areas of expertise in order to advance the field of personalized medicine," said Steven Shak, M.D., chief medical officer, Genomic Health.  "Similar to what Genomic Health found using its quantitative RT-PCR technology in breast and colon cancers, this study shows that renal carcinoma tumors are not all the same and we believe this finding has the potential to provide critical insight for determining how early-stage renal cell carcinoma is treated in the future."  

The clear cell type of renal carcinoma is the most common type of kidney cancer in adults, affecting an estimated 25,000 people each year in the United States, and the incidence of the disease may be increasing.  As part of the collaboration, Genomic Health and Pfizer applied the same molecular technology and clinical strategy Genomic Health used to develop its Oncotype DX® breast and colon cancer tests.


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
2. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
3. Genomic Health to Announce First Quarter 2010 Financial Results and Host Conference Call on Wednesday, May 5, 2010
4. Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services Utilizing the RDT 1000 for Sequence Enrichment and Targeted Resequencing Validation
5. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
6. Transgenomic Reports Fourth Quarter Financial Results
7. AutoGenomics Announces the Launch of a Novel Test for B-RAF Mutations
8. NeoGenomics Schedules Its Q4 and Full Year 2009 Earnings Release for February 25, 2010
9. AutoGenomics Receives ISO Certification
10. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
11. Genomic Health Announces Year-End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ... stock of Solta Medical, Inc. (NASDAQ: SLTM ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Quarter 2011 2011 Fourth Quarter Total Revenue $688.5 million; ... forma organic growth, excluding the impact of foreign exchange and acquisitions, was 10% ... 2011 Fourth Quarter GAAP Operating Cash Flow $190 million; Adjusted Operating ... Total 2011 revenue was $2.46 billion ...
... Inc., (NASDAQ: DCTH ) announced today that ... the Delcath Hepatic CHEMOSAT ® Delivery System at ... treatment and research center located in Frankfurt. The cases were ... agreement the Company announced with the hospital in December ...
Cached Medicine Technology:Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 2Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 3Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 4Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 5Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 6Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 7Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 8Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 9Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 10Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 11Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 12Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 13Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 14Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 15Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 16Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 17Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 18Valeant Pharmaceuticals Reports 2011 Fourth Quarter Financial Results 19Delcath Announces First CHEMOSAT Procedures in Germany 2Delcath Announces First CHEMOSAT Procedures in Germany 3Delcath Announces First CHEMOSAT Procedures in Germany 4
(Date:7/9/2014)... The National Institute of Allergy and Infectious Diseases ... has launched an early-stage clinical trial of CRS3123, ... Clostridium difficile ( C. difficile ) infection. ... agent that inhibits C. difficile growth while sparing ... will enroll up to 30 healthy men and ...
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/8/2014)... and cardiovascular health as other healthy mature individuals, according ... Journal of Transplantation . The findings may provide some ... professionals caring for them. , Over the past two ... and older has become more common. Given the links ... removal of a kidney could make older donors vulnerable ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
Breaking Medicine News(10 mins):Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3
... Aggression, testosterone and nepotism dont necessarily help one climb ... female can, according to new research on the social ... The study, published today in the journal Proceedings of ... status, reproductive physiology and group dynamics. , ...
... Hopkins researchers question government decision to lower requirements ... -- Challenging a recent U.S. government decision to ... heart transplant hospital, a new Johns Hopkins Medical ... from 10 transplants to 14 transplants a year. ...
... new study from the Monell Center increases understanding ... and vomiting that often afflict patients undergoing chemotherapy. ... new approaches to combat these debilitating side effects. ... nausea and vomiting that accompany chemotherapy treatment, we ...
... 30 AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology ... AMICAS are scheduled to,address investors at the UBS Global Healthcare Services ... WHEN: -- Tuesday, ... Presentation begins promptly at 11:30 a.m. (Eastern Time), ...
... 2008 Preventative heart healthcare gains strong momentum today ... involvement as the exclusive radiology provider for the High-Risk ... joint research effort to advance the understanding and management ... primary underlying cause of heart attacks and strokes. ...
... to Nutrition on the Go, an,innovative new program from Diet.com, ... 1,700 restaurants nationwide is available in,a flash through your cell ... item., Not cell phone savvy? No worries. You put ... you need help with, then send that info to,DIET1 (34381). ...
Cached Medicine News:Health News:Females decide whether ambitious males float or flounder 2Health News:Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals 2Health News:Explaining chemotherapy-associated nausea 2Health News:AMICAS to Present at UBS Global Healthcare Services Conference 2Health News:NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative 2Health News:Ring Up Instant Nutrition Info via Text Message to DIET1 (34381) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: